title: [Pulmonary arterial hypertension: changing approaches to management].
abstract: The review is devoted to different aspects of pulmonary arterial hypertension (PAH); new classification of PAH is published in 2010. There are idiopathic PAH and PAH associated with other diseases. Current guidelines recommend to treat PAH only after the verification of diagnosis with right heart catheterization and acute tests with vasodilators. Patients-reactors should be treated with calcium antagonists. The following drugs related to one of three categories should be used in PAH: (1) prostanoids (epoprostenol, iloprost et al.); (2) blockers of endothelin receptors (bosentan, ambrisentan, sitaxsentan); (3) phosphodiesterase 5 type inhibitors (sildenafil, tadalafil et al.) In majority of cases the combined treatment is used, usually the combination of bosentan and sildenafil is used.
authors.forename: B A
authors.initials: BA
authors.lastname: Sidorenko
authors.forename: D V
authors.initials: DV
authors.lastname: Preobrazhenskiĭ
authors.forename: T A
authors.initials: TA
authors.lastname: Batyraliev
authors.forename: Iu N
authors.initials: IuN
authors.lastname: Belenkov
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects; D006328:Cardiac Catheterization; D004059:Diffusion of Innovation; D004359:Drug Therapy, Combination; D065128:Endothelin Receptor Antagonists; D065627:Familial Primary Pulmonary Hypertension; D006321:Heart / Q000503:physiopathology; D006331:Heart Diseases / Q000209:etiology / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008168:Lung / Q000098:blood supply / Q000473:pathology; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D011453:Prostaglandins / Q000008:administration & dosage / Q000009:adverse effects; D011651:Pulmonary Artery / Q000473:pathology / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D017466:Receptors, Endothelin / Q000378:metabolism; D013927:Thrombosis / Q000209:etiology / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000925:Anticoagulants; D002121:Calcium Channel Blockers; D065128:Endothelin Receptor Antagonists; D058986:Phosphodiesterase 5 Inhibitors; D011453:Prostaglandins; D017466:Receptors, Endothelin; D014665:Vasodilator Agents